Abstract 182P
Background
Large desmoplasia, unique tumor microbiome and the immunosuppressive tumor microenvironment has been observed in pancreatic ductal adenocarcinoma (PDAC). Branched polypeptides (BP) are complex engineered structures acting as immunomodulators to control tumor growth. Immune checkpoint inhibitors (ICI) induce antitumor responses, while inhibition of focal adhesion kinase (FAK) reduces fibrosis and boosts immune surveillance. This study aimed to evaluate the in vivo antitumor immune effects and microbiota diversity induced by BP conjugated with PDAC-associated peptide antigens MHCI/II ([BP-MHCI/II]) in combination with an ICI and a FAK inhibitor (FAKi).
Methods
BP were conjugated with MHCI and MHCII-PDAC peptides. To assess the impact of the nanoconjugate on orthotopic PDAC tumor growth, KPC cells were implanted in the pancreas of mice. On day 7, mice were immunized with two doses of either PBS, free antigens/adjuvants (MHCI/MHCII antigens + Toll-like receptor ligands), or [BP-MHCI/II] mixed with adjuvants and combined with ICI and FAKi. Mice weight was monitored regularly. On day 20, PDAC tumors were collected. Functional markers of tumor-infiltrating immune cells were quantified by FACS, and gut and tumor-associated microbiota diversity was analyzed through 16S metagenomic sequencing, followed by QIIME2.11 bioinformatic tools.
Results
[BP-MHCI/II] exhibited a mean diameter of 40 nm and a zeta potential (ZP) of -25 mV, with MHCI and MHCII peptide loading efficiencies of 20% and 13%, respectively. Tumor reduction was more pronounced in mice treated with [BP-MHCI/II] in combination with ICI and FAKi, compared to PBS. The combination treatment modulated tumor-infiltrating immune cells promoting antitumor immunity. Also, gut and tumor microbiota composition and diversity varied among treatments.
Conclusions
The combination of [BP-MHCI/II] with ICI and FAKi represents a promising strategy to overcome tumor growth, to modulate immune cells in tumor microenvironment and microbiota composition in PDAC.
Legal entity responsible for the study
The author.
Funding
Fundação para a Ciência e Tecnologia (FCT).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
134P - Intracranial (IC) progression-free survival (PFS) with ivonescimab (Ivo) compared to placebo in the HARMONi-A trial of patients (Pts) with previously treated EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract
135P - Efficacy and safety of tislelizumab combined with bronchial arterial infusion (BAI) chemotherapy in potentially resectable stage IIIB non-small cell lung cancer(NSCLC): A prospective, single-arm phase II clinical study
Presenter: Xu Ma
Session: Poster Display session
Resources:
Abstract
136P - Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous NSCLC (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy: An updated analysis
Presenter: Baohui Han
Session: Poster Display session
Resources:
Abstract
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
Resources:
Abstract
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
Resources:
Abstract
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
Resources:
Abstract
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
Resources:
Abstract
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
Resources:
Abstract
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session
Resources:
Abstract